symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
PROF,9.3325,1.089638,15868,198414550,0,3.1-15.49,-0.3075,Profound Medical Corp.,USD,0001628808,CA74319B5027,74319B502,NASDAQ Capital Market,NASDAQ,Medical Devices,https://www.profoundmedical.com,"Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.","Dr. Arun Swarup Menawat MBA, Ph.D.",Healthcare,CA,131,16474761350,2400 Skymark Avenue,Mississauga,ON,L4W 5K5,4.53885,8.21115,https://financialmodelingprep.com/image-stock/PROF.png,2019-10-29,False,False,True,False,False
